Spots Global Cancer Trial Database for thrombocytopenia
Every month we try and update this database with for thrombocytopenia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma | NCT04797182 | Thrombocytopeni... Cytarabine Caus... Lymphoma | avatrombopag | 18 Years - 70 Years | Sun Yat-sen University | |
| Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | NCT01428635 | Accelerated Pha... Blast Phase Chr... Chronic Phase C... Primary Myelofi... Thrombocytopeni... | Eltrombopag Ola... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma | NCT00794261 | Lymphoma Myeloma | Injection of Pe... Injection of Fi... | 18 Years - | Centre Leon Berard | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study | NCT04631211 | Thrombocytopeni... Hematologic Mal... Bone Marrow Apl... Myeloproliferat... Myelodysplastic... Platelet Refrac... | Thrombosomes Liquid Stored P... | 18 Years - | Cellphire Therapeutics, Inc. | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis | NCT04800458 | Thrombocytopeni... Immune Thromboc... Myelodysplasia | Blood samples | 18 Years - | University Hospital, Bordeaux | |
| Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. | NCT05392647 | Myelodysplastic... | Hetrombopag | 18 Years - | Tongji Hospital | |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00735930 | Anemia Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... Thrombocytopeni... | Alvocidib Hydro... Lenalidomide Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. | NCT01933035 | Immune Thromboc... Chemotherapy In... Myelodysplasia Aplastic Anaemi... | Immune Thromboc... Hypo-proliferat... Control Populat... | 18 Years - | Beth Israel Medical Center | |
| Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia | NCT00004215 | Anemia Leukemia Neutropenia Thrombocytopeni... | filgrastim leridistim cytarabine daunorubicin hy... | 55 Years - | Memorial Sloan Kettering Cancer Center | |
| Registry for Vascular Anomalies Associated With Coagulopathy | NCT00576888 | Multifocal Lymp... Cutaneovisceral... Vascular Anomal... Hemangiomas | no intervention | - | Medical College of Wisconsin | |
| Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission | NCT00305708 | Congenital Ameg... Diamond-blackfa... Fanconi Anemia Leukemia Severe Congenit... Thrombocytopeni... | anti-thymocyte ... busulfan fludarabine pho... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera... | - 17 Years | University of California, San Francisco | |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02805868 | Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni... | Bone Marrow Asp... Laboratory Biom... Siltuximab | 18 Years - | Northwestern University | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | NCT00493181 | Leukemia Chronic Myeloge... Chronic Myeloid... | Interleukin-11 ... | - | M.D. Anderson Cancer Center | |
| TPO-Mimetic Use in Children for Hematopoietic Failure | NCT04478227 | Bone Marrow Fai... Aplastic Anemia Thrombocytopeni... Refractory Cyto... Myelodysplastic... | Romiplostim | 0 Years - 21 Years | University of Iowa | |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | NCT05469737 | Myelodysplastic... | Oral Azacitidin... Placebo for Ora... | 18 Years - | Bristol-Myers Squibb | |
| Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma | NCT05087459 | Thrombocytopeni... | Avatrombopag | 18 Years - | Shanghai Zhongshan Hospital | |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | NCT05053100 | Acute Leukemia Deep Vein Throm... Hematopoietic a... Hodgkin Lymphom... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Thrombocytopeni... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | NCT01428635 | Accelerated Pha... Blast Phase Chr... Chronic Phase C... Primary Myelofi... Thrombocytopeni... | Eltrombopag Ola... | 18 Years - | M.D. Anderson Cancer Center | |
| Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy | NCT06433830 | Thrombocytopeni... Radiotherapy Si... | Hetrombopag Ola... | 18 Years - | Sir Run Run Shaw Hospital | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) | NCT00413283 | Lung Cancer Chemotherapy-In... Non-Small Cell ... Cancer Lung Neoplasms Oncology Solid Tumors Thrombocytopeni... | Romiplostim Placebo Gemcitabine Carboplatin Cisplatin | 18 Years - | Amgen | |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | NCT01500538 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... | Eltrombopag and... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer | NCT00031980 | Anemia Leukemia Neutropenia Thrombocytopeni... | cyclosporine | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) | NCT00961064 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | NCT06001567 | Thrombocytopeni... Hepatocellular ... | Avatrombopag | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer | NCT00031980 | Anemia Leukemia Neutropenia Thrombocytopeni... | cyclosporine | 18 Years - | Alliance for Clinical Trials in Oncology | |
| PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) | NCT02074436 | Hematological M... Thrombocytopeni... | EACA Platelet transf... | 19 Years - | Emory University | |
| Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia | NCT04896528 | Thrombocytopeni... Avatrombopag | Avatrombopag | 18 Years - 85 Years | Peking Union Medical College Hospital | |
| Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | NCT00074165 | Brain and Centr... Drug/Agent Toxi... Lymphoma Thrombocytopeni... | Rituxan Cyclophosphamid... Etoposide Etoposide phosp... Carboplatin Sodium thiosulf... Neupogen Neulasta Cytarabine | 18 Months - 75 Years | OHSU Knight Cancer Institute | |
| Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia | NCT02964325 | Hematologic Mal... Hypoproliferati... | Mirasol platele... Reference plate... | - | Terumo BCTbio | |
| HIV Indicator Diseases in Hospital and Primary Care | NCT05225493 | HIV Infections Primary Health ... Acquired Immuno... Sexually Transm... Herpes Zoster Dermatitis, Seb... Pneumonia Infectious Mono... Psoriasis Candida Infecti... Lymphadenopathy Uterine Cervica... Weight Loss Diarrhea Chroni... Leukopenia Thrombocytopeni... AIDS Defining I... HIV Indicator C... | Peer to peer fe... HIV rapid test | 18 Years - | Erasmus Medical Center | |
| Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma | NCT04673266 | Lymphoma Patien... Thrombocytopeni... | Romiplostim | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | NCT03195010 | Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... B-Cell Non-Hodg... Chronic Lymphoc... Chronic Myeloge... Hematologic and... Hematopoietic C... Myelodysplastic... Primary Myelofi... Secondary Myelo... T-Cell Non-Hodg... Thrombocytopeni... Venous Thromboe... | Platelet Transf... Platelet Transf... | 18 Years - | Fred Hutchinson Cancer Center | |
| Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment | NCT00608738 | Chemotherapeuti... Infection Malnutrition Musculoskeletal... Neutropenia Radiation Toxic... Thrombocytopeni... Unspecified Adu... | informational i... medical chart r... questionnaire a... assessment of t... management of t... | 21 Years - | Northwestern University | |
| Avatrombopag for Thrombocytopenia in People With Cancer | NCT04437953 | Thrombocytopeni... Cancer Liver Diseases | Avatrombopag | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Screening for Hematology Branch Protocols | NCT00001620 | Hematologic Dis... Donors Healthy Volunte... | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) | NCT02074436 | Hematological M... Thrombocytopeni... | EACA Platelet transf... | 19 Years - | Emory University | |
| Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | NCT01147809 | Thrombocytopaen... | Eltrombopag ola... Placebo | 18 Years - | GlaxoSmithKline | |
| A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 | NCT01663441 | Chemotherapy-in... | NL201 NL201 NL201 rhIL-11 | 18 Years - 75 Years | Beijing Northland Biotech. Co., Ltd. | |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies | NCT05672420 | Hematologic Neo... Neutropenia Anemia Thrombocytopeni... Infections Bleeding | umbilical cord ... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Thrombocytopenia Induced by Chemotherapy | NCT03567798 | Thrombocytopeni... | UPLAT Placebo | 18 Years - 55 Years | Socrates School Of Health | |
| Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis | NCT04800458 | Thrombocytopeni... Immune Thromboc... Myelodysplasia | Blood samples | 18 Years - | University Hospital, Bordeaux | |
| Screening for Hematology Branch Protocols | NCT00001620 | Hematologic Dis... Donors Healthy Volunte... | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | NCT00012376 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult... | bryostatin 1 sargramostim laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy | NCT04526886 | Colorectal Canc... Gastric Cancer Esophageal Canc... Ampullary Cance... Small Bowel Can... Appendix Cancer | Algorithm for c... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Thrombocytopenia Induced by Chemotherapy | NCT03567798 | Thrombocytopeni... | UPLAT Placebo | 18 Years - 55 Years | Socrates School Of Health | |
| Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT00614523 | MDS Myelodysplastic... Thrombocytopeni... | Placebo Romiplostim | 18 Years - 90 Years | Amgen | |
| UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | NCT06245746 | Acute Myeloid L... Neutropenia Anemia Thrombocytopeni... Infections Bleeding | umbilical cord ... | 18 Years - 60 Years | Wuhan Union Hospital, China | |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | NCT01168921 | CLL Leukemia | Eltrombopag | 18 Years - | M.D. Anderson Cancer Center | |
| Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma | NCT00794261 | Lymphoma Myeloma | Injection of Pe... Injection of Fi... | 18 Years - | Centre Leon Berard | |
| Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents | NCT00321711 | MDS Myelodysplastic... Thrombocytopeni... | Placebo AMG 531 (Romipl... Azacitidine Decitabine | 18 Years - | Amgen | |
| Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia | NCT02244658 | Antineoplastic ... Thrombocytopeni... Acute Myelocyti... | rhTPO | 15 Years - 75 Years | Shandong University | |
| Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) | NCT03891576 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Niraparib | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | NCT04478123 | Multiple Myelom... Hodgkin Lymphom... Non-Hodgkin Lym... HDT-AHCT | Romiplostim | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | NCT00187109 | Germ Cell Tumor... Hepatic Cancer Neuroblastoma Osteosarcoma Rhabdomyosarcom... | Recombinant Hum... | - 21 Years | St. Jude Children's Research Hospital | |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | NCT01500538 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... | Eltrombopag and... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis | NCT05255003 | Cancer-associat... Thrombocytopeni... | Enoxaparin Dalteparin Tinzaparin | 18 Years - | Ottawa Hospital Research Institute | |
| Aspirin in Patients With Myocardial Infarction and Thrombocytopenia | NCT00501345 | Thrombocytopeni... Myocardial Infa... | Aspirin | - | M.D. Anderson Cancer Center | |
| SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia | NCT00002665 | Leukemia Neutropenia Thrombocytopeni... | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone doxorubicin hyd... etoposide leucovorin calc... mercaptopurine methotrexate prednisone thioguanine vincristine sul... allogeneic bone... radiation thera... | 15 Years - 65 Years | SWOG Cancer Research Network | |
| Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) | NCT00303472 | Thrombocytopeni... MDS Myelodysplastic... Refractory Cyto... | Romiplostim | 18 Years - | Amgen | |
| Prevention of Thrombocytopenia in Glioblastoma Patients | NCT02227576 | Thrombocytopeni... Glioblastoma | Romiplostim | 18 Years - | University Hospital, Lille | |
| Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia | NCT02530515 | Anemia Cancer Fatigue Chronic Lymphoc... Fever Infectious Diso... Lymphadenopathy Lymphocytosis Night Sweats Prolymphocytic ... Recurrent Chron... Richter Syndrom... Secondary Malig... Thrombocytopeni... Weight Loss | Ex Vivo-activat... Laboratory Biom... | - | M.D. Anderson Cancer Center | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors | NCT04609891 | Thrombocytopeni... | Avatrombopag | 18 Years - 75 Years | Anhui Provincial Cancer Hospital | |
| Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy | NCT00471653 | Brain and Centr... Thrombocytopeni... | temozolomide comparative gen... polymorphism an... laboratory biom... pharmacological... radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy | NCT05442632 | Hepatopathy | Hetrombopag Placebo | 18 Years - | Fudan University | |
| Observational Trial of a Therapeutic Platelet Transfusion Regimen | NCT02276651 | Acute Myeloid L... Thrombocytopeni... | 18 Years - 60 Years | Klinikum Nürnberg | ||
| Evaluation, Treatment, and Training for Patients With Blood Disorders | NCT00001397 | Hematologic Dis... | 2 Years - 110 Years | National Institutes of Health Clinical Center (CC) | ||
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot | NCT01615146 | Myelodysplastic... Leukemia | Platelet Transf... | 18 Years - | Ottawa Hospital Research Institute | |
| Evolution of Thromboelastography During Tranexamic Acid Treatment | NCT03801122 | Hematological M... | Tranexamic acid | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Function of Platelets Used for Transfusions | NCT05038722 | Thrombocytopeni... Hematologic Mal... | Platelet transf... | 18 Years - | Örebro University, Sweden |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
